The estimated Net Worth of Capital Iii Lp Aisling Capi... is at least $4.51 Milión dollars as of 23 January 2015. Capital Capi owns over 811,966 units of Agile Therapeutics Inc stock worth over $4,505,533 and over the last 10 years Capital sold AGRX stock worth over $0.
Capital has made over 1 trades of the Agile Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Capital bought 811,966 units of AGRX stock worth $4,750,001 on 23 January 2015.
The largest trade Capital's ever made was buying 811,966 units of Agile Therapeutics Inc stock on 23 January 2015 worth over $4,750,001. On average, Capital trades about 405,983 units every 0 days since 2015. As of 23 January 2015 Capital still owns at least 2,983,797 units of Agile Therapeutics Inc stock.
You can see the complete history of Capital Capi stock trades at the bottom of the page.
Over the last 10 years, insiders at Agile Therapeutics Inc have traded over $2,369,944 worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth $79,522,957 . The most active insiders traders include Advisors Llcperceptive Life..., Ab Investor a Capital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $1,032,678. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth $22,500.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Agile Therapeutics Inc executives and other stock owners filed with the SEC include: